A New Era in the Management of Hypertrophic Cardiomyopathy

Journal article : Review

Hypertrophic cardiomyopathy (HCM) is a prevalent cardiac disease characterized by marked phenotypic variability. Recent advances in diagnosis and treatment have allowed a personalized approach to the treatment of this disease. Depending on the predominant phenotype, management can be tailored to address left ventricular outflow tract obstruction, heart failure, arrhythmia control, and/or sudden cardiac death prevention. This review highlights recent advances that have transformed the therapeutic landscape of HCM. Modern imaging techniques have improved sudden cardiac death risk stratification. The development of myosin inhibitors represents a paradigm shift in the treatment of symptomatic obstructive HCM. Invasive septal reduction techniques have also evolved, with novel approaches such as percutaneous intramyocardial septal radiofrequency ablation and transapical beating-heart septal myectomy. Finally, gene-targeted therapies including replacement, editing and silencing approaches, are emerging as promising strategies for HCM management.

Authors: Perez-Asensio, A; Llamas-Gomez, H; Lara-Palomo, A; Villar-Ruiz, A; Jimenez-Mendez, C

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: IMR Press
• Journal: Reviews in Cardiovascular Medicine
• Volume: 26
• Issue: 10
• Pages: 44503
• Publication date: 2025-10-30
• DOI: 10.31083/rcm44503
• EISSN: 2153-8174
• ISSN: 1530-6550
• Pmid: 41209136
• Language: English
• Keywords: Sudden Cardiac Death Risk Stratification; Myosin Inhibitors; Gene therapy; Septal Reduction Therapies; hypertrophic cardiomyopathy
• Subtype: Review